Tarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meeting

Tarsus Pharmaceuticals (TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY 0.25% in addressing objective measures of disease at the American Society of Cataract and Refractive Surgery 2025 Annual Meeting, taking place April 25-28, 2025, in Los Angeles, Calif. “From new prevalence data in Japan to real-world results in the US, the findings accepted for oral presentation at ASCRS reinforce the global burden of Demodex blepharitis and the potential of XDEMVY to deliver significant improvements in patient outcomes across multiple subtypes, including those with concomitant meibomian gland disease,” said Elizabeth Yeu, M.D., CMO. “We look forward to continuing to generate new evidence to advance the clinical understanding of XDEMVY and its potential impact on this highly prevalent eyelid disease and on the lives of patients.”